London 2012 Chief Executive Paul Deighton and Hugh Robertson, Minister for Sport and the Olympics, took a tour of the facility.

More than 6,250 samples will be analysed throughout the Olympic and Paralympic Games, up to 400 each day which is more than at any other Games. The laboratory, which measures the size of seven tennis courts, will be in operation 24 hours a day, seven days a week.

More 1,000 London 2012 staff will work within the Anti-Doping process and a team of more than 150 anti-doping scientists will carry out the testing at the laboratory, led independently by Professor David Cowan from the Drug Control Centre at King’s College London.

The facility, which has been provided by pharmaceutical company GSK, will be operated by leading anti-doping experts from King’s College London and supported by scientists from around the world.

Paul Deighton said: “Today is an important milestone in the countdown to the Games. Working with one of the world’s best pharmaceutical companies and one of the country’s leading universities we have been able to create a facility to successfully and efficiently process 6,250 tests during the Games which has never been done before. As we unveil the anti-doping lab we recognise the importance of a robust testing system and continue to show that London is ready to stage a successful Games.”

Professor David Cowan, Director of King’s College London’s Drug Control Centre said: “These laboratories are the most high-tech labs in the history of the Games, analysing more samples than ever before. We have developed, with GSK support, super-fast and super-sensitive technologies to be able to detect use of prohibited substances. Our role is to ensure the efficient and effective operation of the lab to deliver robust anti-doping testing for the Games.”

Sir Andrew Witty, CEO of GlaxoSmithKline said: “As a science based organisation, GSK is well placed to help deliver the scale and cutting edge technology required to run an operation like the anti-doping facility for London 2012. We have worked with King’s to put systems in place to enable this laboratory to test more samples than any previous Games and at the same time developing a blueprint for doping operations at future Games.’

The Anti-Doping process during the London 2012 Games will create a legacy of knowledge about operations and processes. In July 2011, GSK signed an agreement with the World Anti-Doping Agency (WADA) to share information about its medicines in development, while LOCOG will debrief on all processes.

You can watch the video below for more information about the laboratory.